vs
Arcellx, Inc.（ACLX）与Adaptive Biotechnologies Corp（ADPT）财务数据对比。点击上方公司名可切换其他公司
Adaptive Biotechnologies Corp的季度营收约是Arcellx, Inc.的43.3倍（$71.7M vs $1.7M）。Adaptive Biotechnologies Corp净利率更高（-18.9% vs -3513.4%，领先3494.5%）。Adaptive Biotechnologies Corp同比增速更快（51.0% vs -89.2%）。Adaptive Biotechnologies Corp自由现金流更多（$1.4M vs $-58.9M）。过去两年Adaptive Biotechnologies Corp的营收复合增速更高（30.8% vs -79.5%）
Arcellx, Inc.是一家处于临床阶段的生物技术企业，专注开发用于治疗血液恶性肿瘤、实体瘤等难治性癌症的CAR-T细胞疗法，其核心管线针对肿瘤领域未被满足的医疗需求，服务全球患者群体。
ExpreS2ion Biotechnologies是一家丹麦生物技术企业，总部位于丹麦霍尔斯霍姆，专注于新型疫苗和免疫疗法产品的研发，在纳斯达克第一北增长市场瑞典板块挂牌上市。
ACLX vs ADPT — 直观对比
营收规模更大
ADPT
是对方的43.3倍
$1.7M
营收增速更快
ADPT
高出140.2%
-89.2%
净利率更高
ADPT
高出3494.5%
-3513.4%
自由现金流更多
ADPT
多$60.4M
$-58.9M
两年增速更快
ADPT
近两年复合增速
-79.5%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $1.7M | $71.7M |
| 净利润 | $-58.1M | $-13.6M |
| 毛利率 | — | 74.6% |
| 营业利润率 | -3850.2% | -17.8% |
| 净利率 | -3513.4% | -18.9% |
| 营收同比 | -89.2% | 51.0% |
| 净利润同比 | -23.4% | 59.7% |
| 每股收益（稀释后） | $-1.01 | $-0.08 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ACLXADPT
| Q4 25 | $1.7M | $71.7M | ||
| Q3 25 | $4.9M | $94.0M | ||
| Q2 25 | $7.6M | $58.9M | ||
| Q1 25 | $8.1M | $52.4M | ||
| Q4 24 | $15.3M | $47.5M | ||
| Q3 24 | $26.0M | $46.4M | ||
| Q2 24 | $27.4M | $43.2M | ||
| Q1 24 | $39.3M | $41.9M |
净利润ACLXADPT
| Q4 25 | $-58.1M | $-13.6M | ||
| Q3 25 | $-55.8M | $9.5M | ||
| Q2 25 | $-52.8M | $-25.6M | ||
| Q1 25 | $-62.3M | $-29.9M | ||
| Q4 24 | $-47.1M | $-33.7M | ||
| Q3 24 | $-25.9M | $-32.1M | ||
| Q2 24 | $-27.2M | $-46.2M | ||
| Q1 24 | $-7.2M | $-47.5M |
毛利率ACLXADPT
| Q4 25 | — | 74.6% | ||
| Q3 25 | — | 80.7% | ||
| Q2 25 | — | 69.4% | ||
| Q1 25 | — | 67.6% | ||
| Q4 24 | — | 62.0% | ||
| Q3 24 | — | 64.1% | ||
| Q2 24 | — | 55.3% | ||
| Q1 24 | — | 56.9% |
营业利润率ACLXADPT
| Q4 25 | -3850.2% | -17.8% | ||
| Q3 25 | -1248.3% | 10.9% | ||
| Q2 25 | -777.4% | -42.5% | ||
| Q1 25 | -847.6% | -56.4% | ||
| Q4 24 | -348.2% | -71.3% | ||
| Q3 24 | -129.1% | -70.3% | ||
| Q2 24 | -127.8% | -109.6% | ||
| Q1 24 | -40.3% | -116.5% |
净利率ACLXADPT
| Q4 25 | -3513.4% | -18.9% | ||
| Q3 25 | -1127.1% | 10.2% | ||
| Q2 25 | -698.6% | -43.5% | ||
| Q1 25 | -766.0% | -56.9% | ||
| Q4 24 | -308.4% | -71.0% | ||
| Q3 24 | -99.4% | -69.1% | ||
| Q2 24 | -99.3% | -107.0% | ||
| Q1 24 | -18.3% | -113.5% |
每股收益（稀释后）ACLXADPT
| Q4 25 | $-1.01 | $-0.08 | ||
| Q3 25 | $-0.99 | $0.06 | ||
| Q2 25 | $-0.94 | $-0.17 | ||
| Q1 25 | $-1.13 | $-0.20 | ||
| Q4 24 | $-0.87 | $-0.22 | ||
| Q3 24 | $-0.48 | $-0.22 | ||
| Q2 24 | $-0.51 | $-0.31 | ||
| Q1 24 | $-0.14 | $-0.33 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $450.3M | $70.5M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $402.4M | $218.8M |
| 总资产 | $604.0M | $512.7M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ACLXADPT
| Q4 25 | $450.3M | $70.5M | ||
| Q3 25 | $461.4M | $55.0M | ||
| Q2 25 | $453.1M | $43.2M | ||
| Q1 25 | $543.3M | $50.6M | ||
| Q4 24 | $587.4M | $47.9M | ||
| Q3 24 | $574.3M | $38.1M | ||
| Q2 24 | $516.7M | $59.8M | ||
| Q1 24 | $573.9M | $71.2M |
股东权益ACLXADPT
| Q4 25 | $402.4M | $218.8M | ||
| Q3 25 | $440.8M | $204.4M | ||
| Q2 25 | $392.2M | $179.7M | ||
| Q1 25 | $416.9M | $190.4M | ||
| Q4 24 | $454.8M | $202.7M | ||
| Q3 24 | $483.0M | $223.8M | ||
| Q2 24 | $487.2M | $241.6M | ||
| Q1 24 | $496.6M | $274.9M |
总资产ACLXADPT
| Q4 25 | $604.0M | $512.7M | ||
| Q3 25 | $655.9M | $490.6M | ||
| Q2 25 | $619.1M | $496.6M | ||
| Q1 25 | $648.1M | $510.9M | ||
| Q4 24 | $711.3M | $539.4M | ||
| Q3 24 | $764.9M | $558.5M | ||
| Q2 24 | $734.3M | $584.9M | ||
| Q1 24 | $779.7M | $620.3M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-58.2M | $2.1M |
| 自由现金流经营现金流 - 资本支出 | $-58.9M | $1.4M |
| 自由现金流率自由现金流/营收 | -3563.4% | 2.0% |
| 资本支出强度资本支出/营收 | 46.2% | 0.9% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-212.6M | $-48.9M |
8季度趋势，按日历期对齐
经营现金流ACLXADPT
| Q4 25 | $-58.2M | $2.1M | ||
| Q3 25 | $-49.2M | $-7.1M | ||
| Q2 25 | $-39.7M | $-12.4M | ||
| Q1 25 | $-63.1M | $-28.5M | ||
| Q4 24 | $-46.0M | $-12.5M | ||
| Q3 24 | $30.7M | $-27.1M | ||
| Q2 24 | $-36.2M | $-17.3M | ||
| Q1 24 | $-31.9M | $-38.4M |
自由现金流ACLXADPT
| Q4 25 | $-58.9M | $1.4M | ||
| Q3 25 | $-49.5M | $-7.5M | ||
| Q2 25 | $-40.2M | $-13.1M | ||
| Q1 25 | $-63.9M | $-29.7M | ||
| Q4 24 | $-47.5M | $-12.6M | ||
| Q3 24 | $28.4M | $-27.4M | ||
| Q2 24 | $-39.5M | $-19.0M | ||
| Q1 24 | $-38.3M | $-39.9M |
自由现金流率ACLXADPT
| Q4 25 | -3563.4% | 2.0% | ||
| Q3 25 | -1000.3% | -8.0% | ||
| Q2 25 | -532.4% | -22.2% | ||
| Q1 25 | -786.4% | -56.7% | ||
| Q4 24 | -311.3% | -26.5% | ||
| Q3 24 | 109.2% | -59.0% | ||
| Q2 24 | -144.1% | -44.1% | ||
| Q1 24 | -97.7% | -95.2% |
资本支出强度ACLXADPT
| Q4 25 | 46.2% | 0.9% | ||
| Q3 25 | 6.0% | 0.4% | ||
| Q2 25 | 6.4% | 1.1% | ||
| Q1 25 | 9.6% | 2.4% | ||
| Q4 24 | 9.8% | 0.2% | ||
| Q3 24 | 8.8% | 0.7% | ||
| Q2 24 | 11.7% | 4.0% | ||
| Q1 24 | 16.4% | 3.6% |
现金转化率ACLXADPT
| Q4 25 | — | — | ||
| Q3 25 | — | -0.75× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ACLX
暂无分部数据
ADPT
| Mrd Business Segment | $61.9M | 86% |
| Immune Medicine Business | $9.8M | 14% |
| Immune Medicine Service Revenue | $100.0K | 0% |
